These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1036 related items for PubMed ID: 11299841

  • 1. Impact of intravesical chemotherapy on recurrence rate of recurrent superficial transitional cell carcinoma of the bladder: results of a meta-analysis.
    Huncharek M, McGarry R, Kupelnick B.
    Anticancer Res; 2001; 21(1B):765-9. PubMed ID: 11299841
    [Abstract] [Full Text] [Related]

  • 2. Impact of intravesical chemotherapy versus BCG immunotherapy on recurrence of superficial transitional cell carcinoma of the bladder: metaanalytic reevaluation.
    Huncharek M, Kupelnick B.
    Am J Clin Oncol; 2003 Aug; 26(4):402-7. PubMed ID: 12902895
    [Abstract] [Full Text] [Related]

  • 3. Intravesical chemotherapy prophylaxis in primary superficial bladder cancer: a meta-analysis of 3703 patients from 11 randomized trials.
    Huncharek M, Geschwind JF, Witherspoon B, McGarry R, Adcock D.
    J Clin Epidemiol; 2000 Jul; 53(7):676-80. PubMed ID: 10941943
    [Abstract] [Full Text] [Related]

  • 4. The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial.
    Divrik RT, Yildirim U, Zorlu F, Ozen H.
    J Urol; 2006 May; 175(5):1641-4. PubMed ID: 16600720
    [Abstract] [Full Text] [Related]

  • 5. The expression of p53 and bcl-2 in superficial bladder transitional cell carcinoma and its role in the outcome of postoperative intravesical chemotherapy.
    Tzai TS, Chow NH, Lin JS, Yang WH, Tong YC.
    Anticancer Res; 1998 May; 18(6B):4717-21. PubMed ID: 9891547
    [Abstract] [Full Text] [Related]

  • 6. Rationale for intravesical chemotherapy in the treatment and prophylaxis of superficial transitional cell carcinoma.
    Soloway MS, Jordan AM, Murphy WM.
    Prog Clin Biol Res; 1989 May; 310():215-36. PubMed ID: 2505268
    [Abstract] [Full Text] [Related]

  • 7. Apparent failure of current intravesical chemotherapy prophylaxis to influence the long-term course of superficial transitional cell carcinoma of the bladder.
    Lamm DL, Riggs DR, Traynelis CL, Nseyo UO.
    J Urol; 1995 May; 153(5):1444-50. PubMed ID: 7714962
    [Abstract] [Full Text] [Related]

  • 8. Multicentric study comparing intravesical chemotherapy alone and with local microwave hyperthermia for prophylaxis of recurrence of superficial transitional cell carcinoma.
    Colombo R, Da Pozzo LF, Salonia A, Rigatti P, Leib Z, Baniel J, Caldarera E, Pavone-Macaluso M.
    J Clin Oncol; 2003 Dec 01; 21(23):4270-6. PubMed ID: 14581436
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Intravesical chemotherapy for maximum prophylaxis of new early phase superficial bladder carcinoma treated by transurethral resection: a combined analysis of trials by the Japanese Urological Cancer Research Group using smoothed hazard function.
    Hinotsu S, Akaza H, Ohashi Y, Kotake T.
    Cancer; 1999 Nov 01; 86(9):1818-26. PubMed ID: 10547556
    [Abstract] [Full Text] [Related]

  • 12. Combined local bladder hyperthermia and intravesical chemotherapy for the treatment of high-grade superficial bladder cancer.
    Gofrit ON, Shapiro A, Pode D, Sidi A, Nativ O, Leib Z, Witjes JA, van der Heijden AG, Naspro R, Colombo R.
    Urology; 2004 Mar 01; 63(3):466-71. PubMed ID: 15028439
    [Abstract] [Full Text] [Related]

  • 13. Intravesical epirubicin versus doxorubicin for superficial bladder tumors (stages pTa and pT1): a randomized prospective study.
    Ali-el-Dein B, el-Baz M, Aly AN, Shamaa S, Ashamallah A.
    J Urol; 1997 Jul 01; 158(1):68-73; discussion 73-4. PubMed ID: 9186325
    [Abstract] [Full Text] [Related]

  • 14. A randomized controlled trial of short-term versus long-term prophylactic intravesical instillation chemotherapy for recurrence after transurethral resection of Ta/T1 transitional cell carcinoma of the bladder.
    Koga H, Kuroiwa K, Yamaguchi A, Osada Y, Tsuneyoshi M, Naito S.
    J Urol; 2004 Jan 01; 171(1):153-7. PubMed ID: 14665865
    [Abstract] [Full Text] [Related]

  • 15. A model to assess the risk of recurrences of superficial bladder carcinoma. A preliminary report based on 27 patients with a two-year follow-up.
    Boccafoschi C, Robutti F, Montefiore F, Betta PG.
    Pathologica; 1992 Jan 01; 84(1091):269-73. PubMed ID: 1465311
    [Abstract] [Full Text] [Related]

  • 16. [Intravesical BCG, mitomycin-C and thiotepa in the prevention of bladder tumor recurrence after operation].
    Wang SH.
    Zhonghua Wai Ke Za Zhi; 1992 Jul 01; 30(7):410-2, 443-4. PubMed ID: 1301342
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Intravesical instillation of bacille Calmette-Guérin for superficial bladder cancer: cost-effectiveness analysis.
    Uchida A, Yonou H, Hayashi E, Iha K, Oda M, Miyazato M, Oshiro Y, Hokama S, Sugaya K, Ogawa Y.
    Urology; 2007 Feb 01; 69(2):275-9. PubMed ID: 17320663
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 52.